Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.
about
Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycyclineIn vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme diseaseAn optimized SYBR Green I/PI assay for rapid viability assessment and antibiotic susceptibility testing for Borrelia burgdorferiHigh-throughput screening identifies three inhibitor classes of the telomere resolvase from the lyme disease spirochetePopulation bottlenecks during the infectious cycle of the Lyme disease spirochete Borrelia burgdorferiGenetics of Borrelia burgdorferiIdentification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.Management of Lyme disease.Borreliosis: recent research, diagnosis, and management.In Vitro Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents.Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.Borrelia burgdorferi resistance to a major skin antimicrobial peptide is independent of outer surface lipoprotein content.In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.
P2860
Q21131821-A3E40360-6AE0-4B78-AB90-B1116A72AF72Q24645683-6FBA5276-B367-488D-AEB5-C40CB3BFAB89Q28544680-EF96F47A-0674-4378-9E2D-23B3591BE62FQ33481564-CAE79F0A-AC1D-4394-B2E3-CEB2D82C0102Q33825799-76D1104D-9C6B-4889-83D6-673C9721C513Q34299547-F158568D-18EB-496C-9D79-119CCD9E4C6DQ35650795-B3BD6008-40D0-48BC-91B2-7FB7412FFA54Q37124900-B2ABDDA6-BBA0-404F-AE6D-ADC36BD35A38Q37157689-B36E4BD7-A811-4EF7-A0EA-B71F6DE439C2Q38695328-81594A3C-4DD1-4F49-BE04-C5D0323FC64FQ41594433-C4500EB1-860D-40C5-B63E-CBFCEC79FF6EQ41904075-B45185EC-591D-496A-8466-0695189E78E9Q42183764-80230118-7C66-4CE0-85A6-759A881EAFB7
P2860
Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antimicrobial susceptibility o ...... now, and what we need to know.
@ast
Antimicrobial susceptibility o ...... now, and what we need to know.
@en
type
label
Antimicrobial susceptibility o ...... now, and what we need to know.
@ast
Antimicrobial susceptibility o ...... now, and what we need to know.
@en
prefLabel
Antimicrobial susceptibility o ...... now, and what we need to know.
@ast
Antimicrobial susceptibility o ...... now, and what we need to know.
@en
P2860
P1476
Antimicrobial susceptibility o ...... now, and what we need to know.
@en
P2093
Klaus-Peter Hunfeld
Volker Brade
P2860
P2888
P304
P356
10.1007/S00508-006-0693-Z
P577
2006-11-01T00:00:00Z